SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-087740
Filing Date
2023-11-16
Accepted
2023-11-16 09:20:20
Documents
12
Period of Report
2023-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea188562-8k_abvcbio.htm   iXBRL 8-K 27508
  Complete submission text file 0001213900-23-087740.txt   199454

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE abvc-20231116.xsd EX-101.SCH 3021
3 XBRL LABEL FILE abvc-20231116_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE abvc-20231116_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT ea188562-8k_abvcbio_htm.xml XML 3216
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 231412639
SIC: 2834 Pharmaceutical Preparations